1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2020, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.
Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 8, 4, 15, 1, 19 and 8 respectively.
Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionAxial Spondyloarthritis - Overview
Axial Spondyloarthritis - Therapeutics Development
Axial Spondyloarthritis - Therapeutics Assessment
Axial Spondyloarthritis - Companies Involved in Therapeutics Development
Axial Spondyloarthritis - Drug Profiles
Axial Spondyloarthritis - Dormant Projects
Axial Spondyloarthritis - Discontinued Products
Axial Spondyloarthritis - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Axial Spondyloarthritis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Axial Spondyloarthritis - Pipeline by 3SBio Inc, H2 2020
- Axial Spondyloarthritis - Pipeline by AbbVie Inc, H2 2020
- Axial Spondyloarthritis - Pipeline by Akeso Inc, H2 2020
- Axial Spondyloarthritis - Pipeline by Alvotech ehf, H2 2020
- Axial Spondyloarthritis - Pipeline by Amgen Inc, H2 2020
- Axial Spondyloarthritis - Pipeline by Annji Pharmaceutical Co Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by AstraZeneca Plc, H2 2020
- Axial Spondyloarthritis - Pipeline by Beijing Eastern Biotech Co Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by Beijing Shenzhou Cell Biotechnology Group Co Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by Bio-Thera Solutions Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by Biocad, H2 2020
- Axial Spondyloarthritis - Pipeline by Biocon Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by BioXpress Therapeutics SA, H2 2020
- Axial Spondyloarthritis - Pipeline by Clover Biopharmaceuticals, H2 2020
- Axial Spondyloarthritis - Pipeline by DNX Biopharmaceuticals Inc, H2 2020
- Axial Spondyloarthritis - Pipeline by Eli Lilly and Co, H2 2020
- Axial Spondyloarthritis - Pipeline by Enzene Biosciences Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by FunPep Co Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by Galapagos NV, H2 2020
- Axial Spondyloarthritis - Pipeline by Hengenix Biotech Inc, H2 2020
- Axial Spondyloarthritis - Pipeline by Huabo Biopharm Co Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by Hualan Biological Engineering Inc, H2 2020
- Axial Spondyloarthritis - Pipeline by Iltoo Pharma, H2 2020
- Axial Spondyloarthritis - Pipeline by Immunwork Inc, H2 2020
- Axial Spondyloarthritis - Pipeline by InSight Biopharmaceuticals Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by Izana Bioscience Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by Luye Pharma Group Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by Mabpharm Ltd, H2 2020
- Axial Spondyloarthritis - Pipeline by Mycenax Biotech Inc, H2 2020
- Axial Spondyloarthritis - Dormant Projects, H2 2020
- Axial Spondyloarthritis - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Axial Spondyloarthritis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- AbbVie Inc
- Akeso Inc
- Alvotech ehf
- Amgen Inc
- Annji Pharmaceutical Co Ltd
- AstraZeneca Plc
- Beijing Eastern Biotech Co Ltd
- Beijing Shenzhou Cell Biotechnology Group Co Ltd
- Bio-Thera Solutions Ltd
- Biocad
- Biocon Ltd
- BioXpress Therapeutics SA
- Clover Biopharmaceuticals
- DNX Biopharmaceuticals Inc
- Eli Lilly and Co
- Enzene Biosciences Ltd
- FunPep Co Ltd
- Galapagos NV
- Hengenix Biotech Inc
- Huabo Biopharm Co Ltd
- Hualan Biological Engineering Inc
- Iltoo Pharma
- Immunwork Inc
- InSight Biopharmaceuticals Ltd
- Izana Bioscience Ltd
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- JiangSu Qyuns Therapeutics Co Ltd
- Luye Pharma Group Ltd
- Mabpharm Ltd
- Mycenax Biotech Inc
- NeuClone Pty Ltd
- Nichi-Iko Pharmaceutical Co Ltd
- Nimbus Therapeutics LLC
- North China Pharmaceutical Group New Drug Research and Development Co Ltd
- Novartis AG
- Pfizer Inc
- Pharmapraxis
- RNAx Ltd
- Roivant Sciences Ltd
- Shandong Danhong Pharmaceutical Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Siam Bioscience Co Ltd
- Sichuan Haisco Pharmaceutical Co Ltd
- Sino Biopharmaceutical Ltd
- siRNAgen Therapeutics Corp
- Sun Pharma Advanced Research Company Ltd
- Suzhou Zelgen Biopharmaceutical Co Ltd
- UCB SA
- Wuhan Institute of Biological Products Co Ltd
- Xbrane Biopharma AB
- Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd
